{"transactions":[{"id":695370,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T23:33:34.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the one-year anniversary measured from August 3, 2026 (the \"Vesting Commencement Date\"), and 1/48 monthly thereafter such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":450000,"derivative":{"exercise_price":3.17,"expiration_date":"2036-08-02","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001610717-26-000351","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000351/form4.xml","form_type":"4"}},{"id":695369,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":26169,"kind":"person","name":"Carvajal Alejandra","position":1,"cik":"0001645755","reported_name":"Carvajal Alejandra","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-05T23:33:34.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 25% of the RSUs vest annually on September 15 of each year, with the first 25% vesting on September 15, 2027, subject to the Reporting Person's continued service to the Issuer through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 100,000 RSUs."}],"balance_after":100000,"source":{"system":"sec-edgar","filing":"0001610717-26-000351","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000351/form4.xml","form_type":"4"}},{"id":700521,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":24149,"kind":"person","name":"Fuchs Charles S.","position":1,"cik":"0001719576","reported_name":"Fuchs Charles S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-30T21:07:20.000Z","date":"2026-07-24","kind":"grant","planned":false,"acquired":true,"shares":118000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from July 24, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":118000,"derivative":{"exercise_price":3.24,"expiration_date":"2036-07-23","underlying":"Common Stock","underlying_shares":118000},"source":{"system":"sec-edgar","filing":"0001610717-26-000345","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000345/form4.xml","form_type":"4"}},{"id":730155,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36261,"kind":"person","name":"Su Zhen","position":1,"cik":"0001991642","reported_name":"Su Zhen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:53:26.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000280","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000280/form4.xml","form_type":"4"}},{"id":730156,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36262,"kind":"person","name":"Young Matthew P.","position":1,"cik":"0001601583","reported_name":"Young Matthew P.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:52:26.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000279","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000279/form4.xml","form_type":"4"}},{"id":730153,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:50:35.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000278","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000278/form4.xml","form_type":"4"}},{"id":730164,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":16123,"kind":"person","name":"Meyers James R","position":1,"cik":"0001387521","reported_name":"Meyers James R","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:49:39.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000277","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387521/000161071726000277/form4.xml","form_type":"4"}},{"id":730154,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36260,"kind":"person","name":"Gilbert Halley E","position":1,"cik":"0001601360","reported_name":"Gilbert Halley E","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:48:32.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000276","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000276/form4.xml","form_type":"4"}},{"id":730675,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36390,"kind":"person","name":"Ashworth Alan","position":1,"cik":"0001886426","reported_name":"Ashworth Alan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:47:34.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000275","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886426/000161071726000275/form4.xml","form_type":"4"}},{"id":730386,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36310,"kind":"person","name":"Jones Elaine V","position":1,"cik":"0001296907","reported_name":"Jones Elaine V","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:45:37.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000274","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296907/000161071726000274/form4.xml","form_type":"4"}},{"id":733536,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-17T22:38:53.000Z","date":"2026-06-15","kind":"sale","planned":false,"acquired":false,"shares":1624,"price":3.05,"value":4953.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 167,249 RSUs."}],"balance_after":295324,"source":{"system":"sec-edgar","filing":"0001610717-26-000229","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000229/form4.xml","form_type":"4"}},{"id":833190,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-03-19T22:35:34.000Z","date":"2026-03-17","kind":"sale","planned":true,"acquired":false,"shares":118969,"price":6.423,"value":764137.887,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 457,500 RSUs."}],"balance_after":1078922,"source":{"system":"sec-edgar","filing":"0001610717-26-000124","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000124/form4.xml","form_type":"4"}},{"id":833189,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T22:21:13.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":19323,"price":6.423,"value":124111.629,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 173,082 RSUs."}],"balance_after":296948,"source":{"system":"sec-edgar","filing":"0001610717-26-000122","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000122/form4.xml","form_type":"4"}},{"id":833602,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-19T18:41:25.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":21279,"price":6.423,"value":136675.017,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,833 RSUs."}],"balance_after":189446,"source":{"system":"sec-edgar","filing":"0001610717-26-000125","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071726000125/form4.xml","form_type":"4"}},{"id":833690,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-03-19T18:25:33.000Z","date":"2026-03-17","kind":"sale","planned":false,"acquired":false,"shares":31492,"price":6.423,"value":202273.116,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 135,833 RSUs."}],"balance_after":300760,"source":{"system":"sec-edgar","filing":"0001610717-26-000123","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071726000123/form4.xml","form_type":"4"}},{"id":919142,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:23:47.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":325000,"derivative":{"exercise_price":6.09,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001610717-26-000040","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000040/form4.xml","form_type":"4"}},{"id":919141,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:23:47.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 239,987 RSUs."}],"balance_after":316271,"source":{"system":"sec-edgar","filing":"0001610717-26-000040","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000040/form4.xml","form_type":"4"}},{"id":919140,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:22:15.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":980000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":980000,"derivative":{"exercise_price":6.09,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":980000},"source":{"system":"sec-edgar","filing":"0001610717-26-000039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000039/form4.xml","form_type":"4"}},{"id":919139,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2026-02-04T21:22:15.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 698,750 RSUs."}],"balance_after":1197891,"source":{"system":"sec-edgar","filing":"0001610717-26-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000039/form4.xml","form_type":"4"}},{"id":919780,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":67784,"kind":"person","name":"Lester Rachael","position":1,"cik":"0002094324","reported_name":"Lester Rachael","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2026-02-04T16:28:36.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001610717-26-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2094324/000161071726000043/form4.xml","form_type":"4"}},{"id":919779,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":67784,"kind":"person","name":"Lester Rachael","position":1,"cik":"0002094324","reported_name":"Lester Rachael","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:28:36.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":50000,"derivative":{"exercise_price":6.09,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001610717-26-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2094324/000161071726000043/form4.xml","form_type":"4"}},{"id":919778,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":67784,"kind":"person","name":"Lester Rachael","position":1,"cik":"0002094324","reported_name":"Lester Rachael","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-02-04T16:28:36.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 20,000 RSUs."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001610717-26-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2094324/000161071726000043/form4.xml","form_type":"4"}},{"id":919583,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:27:02.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":300000,"derivative":{"exercise_price":6.09,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001610717-26-000042","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071726000042/form4.xml","form_type":"4"}},{"id":919582,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-04T16:27:02.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 206,000 RSUs."}],"balance_after":210725,"source":{"system":"sec-edgar","filing":"0001610717-26-000042","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071726000042/form4.xml","form_type":"4"}},{"id":919637,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:25:27.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":250000,"derivative":{"exercise_price":6.09,"expiration_date":"2036-02-01","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001610717-26-000041","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071726000041/form4.xml","form_type":"4"}},{"id":919636,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-04T16:25:27.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 218,958 RSUs."}],"balance_after":332252,"source":{"system":"sec-edgar","filing":"0001610717-26-000041","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071726000041/form4.xml","form_type":"4"}},{"id":1003492,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Class A Common Stock","published_at":"2025-11-10T21:05:32.000Z","date":"2025-11-06","kind":"sale","planned":true,"acquired":false,"shares":101793,"price":4.5377,"value":461906.0961,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on August 27, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.50 to $4.62, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 488,750 restricted stock units."}],"balance_after":987891,"source":{"system":"sec-edgar","filing":"0001610717-25-000372","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000372/form4.xml","form_type":"4"}},{"id":1012174,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":67784,"kind":"person","name":"Lester Rachael","position":1,"cik":"0002094324","reported_name":"Lester Rachael","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-29T16:50:51.000Z","date":"2025-10-20","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the one year anniversary measured from October 20, 2025 (the \"Vesting Commencement Date\"), and 1/48th of the shares will vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":650000,"derivative":{"exercise_price":3.74,"expiration_date":"2035-10-19","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0001610717-25-000370","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2094324/000161071725000370/form4.xml","form_type":"4"}},{"id":1030383,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Performance Stock Units (PSUs)","published_at":"2025-09-30T22:40:05.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":285000,"derivative":{"underlying":"Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001610717-25-000357","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000357/form4.xml","form_type":"4"}},{"id":1030382,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-30T22:40:05.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":570000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":570000,"derivative":{"exercise_price":2.9,"expiration_date":"2035-09-25","underlying":"Common Stock","underlying_shares":570000},"source":{"system":"sec-edgar","filing":"0001610717-25-000357","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000357/form4.xml","form_type":"4"}},{"id":1030381,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2025-09-30T22:38:27.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":39150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":39150,"derivative":{"underlying":"Common Stock","underlying_shares":39150},"source":{"system":"sec-edgar","filing":"0001610717-25-000355","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000355/form4.xml","form_type":"4"}},{"id":1030380,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-30T22:38:27.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":78250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":78250,"derivative":{"exercise_price":2.9,"expiration_date":"2035-09-25","underlying":"Common Stock","underlying_shares":78250},"source":{"system":"sec-edgar","filing":"0001610717-25-000355","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000355/form4.xml","form_type":"4"}},{"id":1030621,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2025-09-30T18:39:31.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":43750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":43750,"derivative":{"underlying":"Common Stock","underlying_shares":43750},"source":{"system":"sec-edgar","filing":"0001610717-25-000356","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071725000356/form4.xml","form_type":"4"}},{"id":1030620,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-30T18:39:31.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":87500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":87500,"derivative":{"exercise_price":2.9,"expiration_date":"2035-09-25","underlying":"Common Stock","underlying_shares":87500},"source":{"system":"sec-edgar","filing":"0001610717-25-000356","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071725000356/form4.xml","form_type":"4"}},{"id":1030650,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2025-09-30T18:37:42.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":18150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Performance Stock Unit (\"PSU\") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":18150,"derivative":{"underlying":"Common Stock","underlying_shares":18150},"source":{"system":"sec-edgar","filing":"0001610717-25-000354","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000354/form4.xml","form_type":"4"}},{"id":1030649,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-30T18:37:42.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":36300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":36300,"derivative":{"exercise_price":2.9,"expiration_date":"2035-09-25","underlying":"Common Stock","underlying_shares":36300},"source":{"system":"sec-edgar","filing":"0001610717-25-000354","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000354/form4.xml","form_type":"4"}},{"id":1107597,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1107596,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-16","kind":"sale","planned":false,"acquired":false,"shares":10614,"price":2.6889,"value":28539.9846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,987 RSUs."}],"balance_after":226271,"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1107595,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This transaction represents the vesting of performance stock units (\"PSUs\") initially granted on February 2, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,987 RSUs."}],"balance_after":236885,"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1107594,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-17T20:11:18.000Z","date":"2025-06-13","kind":"sale","planned":false,"acquired":false,"shares":1641,"price":2.9503,"value":4841.4423,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 149,987 RSUs."}],"balance_after":199385,"source":{"system":"sec-edgar","filing":"0001610717-25-000236","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000236/form4.xml","form_type":"4"}},{"id":1107593,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Performance Stock Units","published_at":"2025-06-17T20:09:02.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001610717-25-000234","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000234/form4.xml","form_type":"4"}},{"id":1107592,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-06-17T20:09:02.000Z","date":"2025-06-16","kind":"sale","planned":false,"acquired":false,"shares":55511,"price":2.6889,"value":149263.5279,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 488,750 restricted stock units."}],"balance_after":1089684,"source":{"system":"sec-edgar","filing":"0001610717-25-000234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000234/form4.xml","form_type":"4"}},{"id":1107591,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-06-17T20:09:02.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents the vesting of performance stock units (\"PSUs\") initially granted on February 2, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 488,750 restricted stock units."}],"balance_after":1145195,"source":{"system":"sec-edgar","filing":"0001610717-25-000234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000234/form4.xml","form_type":"4"}},{"id":1108299,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units","published_at":"2025-06-17T16:10:00.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represented a contingent right to receive one (1) share of common stock upon vesting."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001610717-25-000235","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000235/form4.xml","form_type":"4"}},{"id":1108298,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-17T16:10:00.000Z","date":"2025-06-16","kind":"sale","planned":false,"acquired":false,"shares":13884,"price":2.689,"value":37334.076,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 158,958 restricted stock units."}],"balance_after":272252,"source":{"system":"sec-edgar","filing":"0001610717-25-000235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000235/form4.xml","form_type":"4"}},{"id":1108297,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-06-17T16:10:00.000Z","date":"2025-06-13","kind":"exercise","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents the vesting of performance stock units (\"PSUs\") initially granted on February 2, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 158,958 restricted stock units."}],"balance_after":286136,"source":{"system":"sec-edgar","filing":"0001610717-25-000235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000235/form4.xml","form_type":"4"}},{"id":1111132,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36261,"kind":"person","name":"Su Zhen","position":1,"cik":"0001991642","reported_name":"Su Zhen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:19:11.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000215","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000215/form4.xml","form_type":"4"}},{"id":1111131,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36262,"kind":"person","name":"Young Matthew P.","position":1,"cik":"0001601583","reported_name":"Young Matthew P.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:18:47.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000214","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000214/form4.xml","form_type":"4"}},{"id":1111130,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:18:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000213/form4.xml","form_type":"4"}},{"id":1111169,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":16123,"kind":"person","name":"Meyers James R","position":1,"cik":"0001387521","reported_name":"Meyers James R","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:17:50.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000212","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387521/000161071725000212/form4.xml","form_type":"4"}},{"id":1111382,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36310,"kind":"person","name":"Jones Elaine V","position":1,"cik":"0001296907","reported_name":"Jones Elaine V","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:17:23.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000211","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296907/000161071725000211/form4.xml","form_type":"4"}},{"id":1111129,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36260,"kind":"person","name":"Gilbert Halley E","position":1,"cik":"0001601360","reported_name":"Gilbert Halley E","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:16:56.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000210","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000210/form4.xml","form_type":"4"}},{"id":1112015,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36390,"kind":"person","name":"Ashworth Alan","position":1,"cik":"0001886426","reported_name":"Ashworth Alan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:16:15.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000209","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1886426/000161071725000209/form4.xml","form_type":"4"}},{"id":1195472,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-03-20T20:34:40.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":37656,"price":0.599,"value":22555.944,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 488,750 RSUs."}],"balance_after":995195,"source":{"system":"sec-edgar","filing":"0001610717-25-000086","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000086/form4.xml","form_type":"4"}},{"id":1195473,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-20T20:33:49.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":8551,"price":0.599,"value":5122.049,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 155,821 RSUs."}],"balance_after":201026,"source":{"system":"sec-edgar","filing":"0001610717-25-000085","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000085/form4.xml","form_type":"4"}},{"id":1195807,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-20T16:32:56.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":4025,"price":0.599,"value":2410.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 131,000 RSUs."}],"balance_after":135725,"source":{"system":"sec-edgar","filing":"0001610717-25-000084","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071725000084/form4.xml","form_type":"4"}},{"id":1195522,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2025-03-20T16:32:22.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":10203,"price":0.599,"value":6111.597,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 30,624 RSUs."}],"balance_after":120594,"source":{"system":"sec-edgar","filing":"0001610717-25-000083","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071725000083/form4.xml","form_type":"4"}},{"id":1195881,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-03-20T16:31:34.000Z","date":"2025-03-18","kind":"sale","planned":false,"acquired":false,"shares":19512,"price":0.599,"value":11687.688,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 158,958 RSUs."}],"balance_after":248636,"source":{"system":"sec-edgar","filing":"0001610717-25-000082","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000082/form4.xml","form_type":"4"}},{"id":1276806,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":115000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1276805,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":150000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1276804,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 201,666 RSUs."}],"balance_after":268148,"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1276803,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-10T17:58:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."},{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Form 4 filed by the Reporting Person on February 6, 2025 incorrectly reflected the number of securities acquired in Box 4 of Table I and Box 5 of Table II and consequently the amount beneficially owned reflected in Box 5 of Table I and Box 9 of Table II.  The number of securities acquired and the amount beneficially owned following reported transactions has been adjusted in this Form 4/A to correct the aforementioned errors. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported."}],"balance_after":210648,"source":{"system":"sec-edgar","filing":"0001610717-25-000020","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000020/form4.xml","form_type":"4/A","original_submission_date":"2025-02-06"}},{"id":1280107,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":115000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1280106,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":225000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1280105,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 179,310 RSUs."}],"balance_after":209577,"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1280104,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-06T22:55:15.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":152077,"source":{"system":"sec-edgar","filing":"0001610717-25-000017","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000017/form4.xml","form_type":"4"}},{"id":1280103,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T22:54:34.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":390000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":390000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":390000},"source":{"system":"sec-edgar","filing":"0001610717-25-000016","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000016/form4.xml","form_type":"4"}},{"id":1280102,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T22:54:34.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":800000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001610717-25-000016","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000016/form4.xml","form_type":"4"}},{"id":1280101,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-02-06T22:54:34.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 572,500 RSUs."}],"balance_after":1032851,"source":{"system":"sec-edgar","filing":"0001610717-25-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000016/form4.xml","form_type":"4"}},{"id":1280100,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2025-02-06T22:54:34.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":837851,"source":{"system":"sec-edgar","filing":"0001610717-25-000016","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000016/form4.xml","form_type":"4"}},{"id":1280463,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":115000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1280462,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":140000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":140000},"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1280461,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 196,666 RSUs."}],"balance_after":263148,"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1280460,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-06T17:57:43.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":205648,"source":{"system":"sec-edgar","filing":"0001610717-25-000019","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071725000019/form4.xml","form_type":"4"}},{"id":1280407,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T17:55:51.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/24th of the shares subject to the option vest on each monthly anniversary measured from the Vesting Commencement Date, such that 100% of the shares subject to the option will be fully vested and exercisable on the second anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":115000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001610717-25-000018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071725000018/form4.xml","form_type":"4"}},{"id":1280406,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-06T17:55:51.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":238000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from February 4, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":238000,"derivative":{"exercise_price":0.864,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":238000},"source":{"system":"sec-edgar","filing":"0001610717-25-000018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071725000018/form4.xml","form_type":"4"}},{"id":1280405,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-06T17:55:51.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":57500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Constitute RSUs for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest annually on March 15 of each year, with the first 50% vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 139,750 RSUs."}],"balance_after":139750,"source":{"system":"sec-edgar","filing":"0001610717-25-000018","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071725000018/form4.xml","form_type":"4"}},{"id":1280404,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57158,"kind":"person","name":"Chu Yu-Waye","position":1,"cik":"0001854586","reported_name":"Chu Yu-Waye","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-06T17:55:51.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2026, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":82250,"source":{"system":"sec-edgar","filing":"0001610717-25-000018","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1854586/000161071725000018/form4.xml","form_type":"4"}},{"id":1425032,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T22:01:51.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-24-000436","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000436/form4.xml","form_type":"4"}},{"id":1425031,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-08-22T22:01:51.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":4181,"price":1.2291,"value":5138.8671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 64,802 restricted stock units."}],"balance_after":119056,"source":{"system":"sec-edgar","filing":"0001610717-24-000436","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000436/form4.xml","form_type":"4"}},{"id":1425030,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":88063,"kind":"person","name":"Landau Jeffrey B","position":1,"cik":"0001918615","reported_name":"Landau Jeffrey B","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-08-22T22:01:51.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,927 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 64,802 restricted stock units."}],"balance_after":123237,"source":{"system":"sec-edgar","filing":"0001610717-24-000436","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000436/form4.xml","form_type":"4"}},{"id":1425029,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T21:59:48.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6875},"source":{"system":"sec-edgar","filing":"0001610717-24-000433","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000433/form4.xml","form_type":"4"}},{"id":1425028,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-22T21:59:48.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":1984,"price":1.2291,"value":2438.5344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77,810 restricted stock units."}],"balance_after":108077,"source":{"system":"sec-edgar","filing":"0001610717-24-000433","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000433/form4.xml","form_type":"4"}},{"id":1425027,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-22T21:59:48.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":6875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77,810 restricted stock units."}],"balance_after":110061,"source":{"system":"sec-edgar","filing":"0001610717-24-000433","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000433/form4.xml","form_type":"4"}},{"id":1425026,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T21:58:38.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001610717-24-000432","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000432/form4.xml","form_type":"4"}},{"id":1425025,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-08-22T21:58:38.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":13898,"price":1.2291,"value":17082.0318,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 197,500 restricted stock units."}],"balance_after":657851,"source":{"system":"sec-edgar","filing":"0001610717-24-000432","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000432/form4.xml","form_type":"4"}},{"id":1425024,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57063,"kind":"person","name":"McCarthy Sean A.","position":1,"cik":"0001654058","reported_name":"McCarthy Sean A.","relationship":{"director":true,"officer":true,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-08-22T21:58:38.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 197,500 restricted stock units."}],"balance_after":671749,"source":{"system":"sec-edgar","filing":"0001610717-24-000432","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000432/form4.xml","form_type":"4"}},{"id":1425671,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T18:01:09.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-24-000435","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000435/form4.xml","form_type":"4"}},{"id":1425670,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-22T18:01:09.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":4181,"price":1.2291,"value":5138.8671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,166 restricted stock units."}],"balance_after":175648,"source":{"system":"sec-edgar","filing":"0001610717-24-000435","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000435/form4.xml","form_type":"4"}},{"id":1425669,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":57180,"kind":"person","name":"BELVIN MARCIA","position":1,"cik":"0001970752","reported_name":"BELVIN MARCIA","relationship":{"officer":true,"officer_title":"SVP, Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-22T18:01:09.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 109,166 restricted stock units."}],"balance_after":179829,"source":{"system":"sec-edgar","filing":"0001610717-24-000435","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970752/000161071724000435/form4.xml","form_type":"4"}},{"id":1425118,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Performance Stock Units (PSUs)","published_at":"2024-08-22T18:00:30.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":false,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001610717-24-000434","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000434/form4.xml","form_type":"4"}},{"id":1425117,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-22T18:00:30.000Z","date":"2024-08-20","kind":"sale","planned":false,"acquired":false,"shares":4181,"price":1.2291,"value":5138.8671,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 52,916 restricted stock units."}],"balance_after":130797,"source":{"system":"sec-edgar","filing":"0001610717-24-000434","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000434/form4.xml","form_type":"4"}},{"id":1425116,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":81699,"kind":"person","name":"ROWLAND LLOYD A","position":1,"cik":"0001236395","reported_name":"ROWLAND LLOYD A","relationship":{"officer":true,"officer_title":"General Counsel"}}],"security":"Common Stock","published_at":"2024-08-22T18:00:30.000Z","date":"2024-08-20","kind":"exercise","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents vesting of a Performance Stock Unit (\"PSU\") award initially granted on August 10, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 52,916 restricted stock units."}],"balance_after":134978,"source":{"system":"sec-edgar","filing":"0001610717-24-000434","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1236395/000161071724000434/form4.xml","form_type":"4"}},{"id":1478614,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:24:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to the option vest on each monthly anniversary measured from June 12, 2024 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":75000,"derivative":{"exercise_price":1.49,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001610717-24-000339","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000339/form4.xml","form_type":"4"}},{"id":1478613,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":37157,"kind":"person","name":"Ogden Christopher","position":1,"cik":"0001914523","reported_name":"Ogden Christopher","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-14T20:24:33.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on June 12 of each year, with the first 1/3rd vesting on June 12, 2025, subject to the Reporting Person continuing as a service provider through each such date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77,810 RSUs."}],"balance_after":103186,"source":{"system":"sec-edgar","filing":"0001610717-24-000339","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000339/form4.xml","form_type":"4"}},{"id":1510699,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36262,"kind":"person","name":"Young Matthew P.","position":1,"cik":"0001601583","reported_name":"Young Matthew P.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T21:36:18.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.96,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-24-000248","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000248/form4.xml","form_type":"4"}},{"id":1510698,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36261,"kind":"person","name":"Su Zhen","position":1,"cik":"0001991642","reported_name":"Su Zhen","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T21:36:07.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.96,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-24-000247","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000247/form4.xml","form_type":"4"}},{"id":1510697,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T21:34:38.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.98,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-24-000246","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000246/form4.xml","form_type":"4"}},{"id":1510712,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":16123,"kind":"person","name":"Meyers James R","position":1,"cik":"0001387521","reported_name":"Meyers James R","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T21:34:02.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.96,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-24-000245","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1387521/000161071724000245/form4.xml","form_type":"4"}},{"id":1511030,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":36310,"kind":"person","name":"Jones Elaine V","position":1,"cik":"0001296907","reported_name":"Jones Elaine V","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T21:33:14.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.96,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-24-000244","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296907/000161071724000244/form4.xml","form_type":"4"}}],"next_cursor":"2024-05-17T21:33:14.000000Z,1511030"}